Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report details a specific share repurchase transaction executed on April 8, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 750,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,229 pence per share; lowest price paid was 1,217.5 pence per share.
- Treasury Holdings: Following cancellation, the Company holds 493,224,284 shares in Treasury.
- Treasury Percentage: Represents 8.71% of total issued share capital and 9.54% of total voting rights.
- Shares in Issue: 5,167,649,574 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 750,000 repurchased shares. This action increased the proportion of Treasury shares held by the Company relative to total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (5,167,649,574) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (493,224,284) and its impact on voting rights (9.54%).
- Note that the repurchased shares were cancelled rather than held indefinitely as treasury stock without cancellation.